Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1)
G. Gentilini et al., Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1), BLOOD, 93(1), 1999, pp. 25-33
Human PF4 is a heparin-binding chemokine known to be capable of inhibiting
endothelial cell proliferation and angiogenesis. To explore the biological
mechanisms responsible for this action, we investigated the effect of PF4 o
n epidermal growth factor (EGF)-stimulated human umbilical vein endothelial
cells (HUVEC), a model system in which stimulation is essentially independ
ent of interaction with cell-surface glycosaminoglycans. Based on previous
findings that PF4 blocks endothelial cell cycle entry and progression into
S phase, we studied the molecular mechanism(s) of PF4 interference with cel
l cycle machinery. PF4 treatment of EGF-stimulated HUVEC caused a decrease
in cyclin E-cyclin-dependent kinase 2 (cdk2) activity with resulting attenu
ation of retinoblastoma protein phosphorylation. PF4-dependent downregulati
on of cyclin E-cdk2 activity was associated with increased binding of the c
yclin-dependent kinase inhibitor, p21(Cip1/WAF1), to the cyclin E-cdk2 comp
lex. Analysis of total cellular p21(Cip1/WAF1) showed that in the presence
of PF4, p21(Cip1/WAF1) levels were sustained at time points when p21(Cip1/W
AF1) was no longer detectable in cells stimulated by EGF in the absence of
PF4. These findings indicate that PF4 inhibition of HUVEC proliferation in
response to EGF is associated with impaired downregulation of p21(Cip1/WAF1
) and provide the first evidence for interference with cell cycle mechanism
s by a chemokine. (C) 1999 by The American Society of Hematology.